Recombinant Anti-CD19 × Anti-CD3 Bispecific Antibody (CrossMab)
CAT#: CROSS-L024
Recombinant Anti-CD19 × Anti-CD3 Bispecific Antibody (CrossMab) has been generated by applying the Crossmab format to generate an IgG shaped entity that binds each ligand with one arm. This BsAb is capable of targeting the tumor and recruiting T effector cells via binding to the CD3 subunit of the T cell receptor complex. It was designed for the treatment of non-Hodgkin's lymphoma.
Specifications
- Target
- CD19 & CD3
- Type
- CrossMab
- Species Reactivity
- Human
- Target 1
- CD19
- Host Species 1
- Mouse
- Target 2
- CD3
- Host Species 2
- Mouse
- Application
- FuncS, Promising therapeutic agent
- Related Disease
- Non-Hodgkin's lymphoma
Target
- Target 1
- CD19
- Gene ID
- 930
- UniProt ID
- P15391
- Alternative Names
- CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
- Target 2
- CD3
- Gene ID
- 916
- UniProt ID
- P07766
- Alternative Names
- CD3E; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for CROSS-L024. Click the button above to contact us or submit your feedback about this product.
Excellent T Cell Recruitment
This bispecific antibody worked perfectly in our T cell redirection assays. We observed a clear bridging effect between the effector T cells and the CD19 positive B lymphoma cells, leading to measurable activation markers in our flow cytometry readout.
High Purity And Consistency
We have tried several bispecific formats, but this CrossMab design showed superior purity with very little aggregation. It was very helpful for our mechanism of action studies regarding non-Hodgkin's lymphoma, as it minimized the background noise often caused by chain mispairing.
Q&As
-
How does the CrossMab format benefit my bispecific antibody experiments?
A: The CrossMab format we utilize generates an IgG-shaped entity that effectively minimizes chain mispairing during production. This ensures a high purity of the heterodimeric bispecific antibody, providing you with a stable and reliable reagent for your T cell recruitment and B cell targeting assays without the complications of homodimer contaminants.
-
What are the two targets of this bispecific antibody and its intended use?
A: This bispecific antibody targets CD19 on B cells and CD3 on T cells. It is capable of binding both cell types simultaneously, recruiting cytotoxic T effector cells to the tumor site. It is designed primarily for research into immunotherapy strategies for treating non-Hodgkin's lymphoma.
View the frequently asked questions answered by Creative Biolabs Support.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
-2.png)
Application: WB, ELISA
Application: Neut, FC
Application: ELISA, WB, Neut, Funcs, IHC, Inhib
Application: ELISA, Inhib, FuncS
-2.png)
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
